These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38029832)

  • 1. The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines.
    Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Nabeshima S; Hiromatsu K
    Int J Infect Dis; 2024 Feb; 139():1-5. PubMed ID: 38029832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations.
    Akhtar M; Islam MR; Khaton F; Soltana UH; Jafrin SA; Rahman SIA; Tauheed I; Ahmed T; Khan II; Akter A; Khan ZH; Islam MT; Khanam F; Biswas PK; Ahmmed F; Ahmed S; Rashid MM; Hossain MZ; Alam AN; Alamgir ASM; Rahman M; Ryan ET; Harris JB; LaRocque RC; Flora MS; Chowdhury F; Khan AI; Banu S; Shirin T; Bhuiyan TR; Qadri F
    Front Immunol; 2023; 14():1309997. PubMed ID: 38173725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
    Buhre JS; Pongracz T; Künsting I; Lixenfeld AS; Wang W; Nouta J; Lehrian S; Schmelter F; Lunding HB; Dühring L; Kern C; Petry J; Martin EL; Föh B; Steinhaus M; von Kopylow V; Sina C; Graf T; Rahmöller J; Wuhrer M; Ehlers M
    Front Immunol; 2022; 13():1020844. PubMed ID: 36713457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
    Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
    J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2.
    Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Sechi Y; Fujikane A; Nabeshima S; Hiromatsu K
    Heliyon; 2024 Jan; 10(1):e23595. PubMed ID: 38187240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history.
    Kiszel P; Sík P; Miklós J; Kajdácsi E; Sinkovits G; Cervenak L; Prohászka Z
    Sci Rep; 2023 Aug; 13(1):13166. PubMed ID: 37574522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection.
    Sheikh-Mohamed S; Isho B; Chao GYC; Zuo M; Cohen C; Lustig Y; Nahass GR; Salomon-Shulman RE; Blacker G; Fazel-Zarandi M; Rathod B; Colwill K; Jamal A; Li Z; de Launay KQ; Takaoka A; Garnham-Takaoka J; Patel A; Fahim C; Paterson A; Li AX; Haq N; Barati S; Gilbert L; Green K; Mozafarihashjin M; Samaan P; Budylowski P; Siqueira WL; Mubareka S; Ostrowski M; Rini JM; Rojas OL; Weissman IL; Tal MC; McGeer A; Regev-Yochay G; Straus S; Gingras AC; Gommerman JL
    Mucosal Immunol; 2022 May; 15(5):799-808. PubMed ID: 35468942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
    Nielsen BU; Drabe CH; Barnkob MB; Johansen IS; Hansen AKK; Nilsson AC; Rasmussen LD
    Front Immunol; 2022; 13():934476. PubMed ID: 35967433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
    Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
    Han A; Min S; Jo EA; Lee H; Kim YC; Han SS; Kang HG; Ahn YH; Oh I; Song EY; Ha J
    Ann Lab Med; 2024 Jan; 44(1):64-73. PubMed ID: 37665287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers.
    Kitabatake M; Ouji-Sageshima N; Sonobe S; Furukawa R; Konda M; Hara A; Aoki H; Suzuki Y; Imakita N; Nakano A; Fujita Y; Shichino S; Nakano R; Ueha S; Kasahara K; Muro S; Yano H; Matsushima K; Ito T
    Jpn J Infect Dis; 2023 Jan; 76(1):72-76. PubMed ID: 36047181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.